Respiratory Tract Infection Trial

 

Respiratory Tract Infection Trial

  • For people 65 and older with medical complications, RTIs may be a really serious issue. 1
  • People older than 65 usually get at least one respiratory tract infection (or RTI) each year  2
  • RTIs are one of the most common causes for hospitalization in people older than 65  3
  • RTIs are the 8th leading cause of death in people 65 and older in Australia5, 9th in New Zealand  6.
  • Preclinical scientific evidence suggests that by targeting specific biochemical pathways, we may be able to change the way     aging affects the body and potentially help people live healthier longer  7.

About the clinical study:

resTORbio, a US-based biotechnology company, engaged Continuum Clinical, a patient recruitment company with over 25-years of experience in health care, to host a series of community events to raise awareness of RTIs and associated risk factors. resTORbio is developing innovative medicines that target the biology of aging to prevent or treat age-related diseases. One critical signalling pathway that resTORbio is focused on is known as TORC1. Of the biochemical pathways of aging, inhibition of TORC1 has been observed in preclinical species to extend lifespan and health span, and to improve immune, neurologic and cardiac functions, suggesting that inhibition of TORC1 may have potential benefit in aging-related diseases7.

For more information on resTORbio, please visit www.resTORbio.com